« Back to Exclusive Articles

LDL-Cholesterol & Cardiovascular Disease – Part 2: Smokescreens and Tautologies

This content is restricted to members.

To view our premium content, sign up for a membership:

Register New Account

Username

First Name

Last Name

Password

Password Again

Choose your membership level

Monthly Membership - €24.99 - 1 Month
Full Education Hub access: the weekly Study Deepdive, bi-monthly video Research Lectures, Exclusive Articles, and the full backcatalog of Deepdives in downloadable pdf format.
Annual Membership - €249.99 - 1 Year
Access to all the Education Hub content, at a reduced annual rate.

Discount Code - Valid - Invalid

Choose Your Payment Method

Credit / Debit Card PayPal

I agree to the privacy policy

‹ Back to Exclusive Articles

References

1. O’Keefe J, Cordain L, Harris W, Moe R, Vogel R. Optimal Low-Density Lipoprotein Is 50 to 70 mg/dl Lower Is Better and Physiologically Normal. Journal of the American College of Cardiology. 2004;43(11):2142-2146.

2. Brown M, Goldstein J. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232(4746):34-47.

3. Fodor J, Helis E, Yazdekhasti N, Vohnout B. “Fishing” for the Origins of the “Eskimos and Heart Disease” Story: Facts or Wishful Thinking?. Canadian Journal of Cardiology. 2014;30(8):864-868.

4. Castelli W. Lipids, risk factors and ischaemic heart disease. Atherosclerosis. 1996;124:S1-S9.

5. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. The Lancet. 2007;370(9602):1829-1839.

6. Ference B. Causal Effect of Lipids and Lipoproteins on Atherosclerosis. Cardiology Clinics. 2018;36(2):203-211.

7. Strandberg T. Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients. Current Atherosclerosis Reports. 2019;21(8).

8. Postmus I, Deelen J, Sedaghat S, Trompet S, de Craen A, Heijmans B et al. LDL cholesterol still a problem in old age? A Mendelian randomization study. International Journal of Epidemiology. 2015;44(2):604-612.

9. Storey B, Staplin N, Haynes R, Reith C, Emberson J, Herrington W et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney International. 2018;93(4):1000-1007.

10. Bohula E, Giugliano R, Leiter L, Verma S, Park J, Sever P et al. Inflammatory and Cholesterol Risk in the FOURIER Trial. Circulation. 2018;138(2):131-140.

11. Lawler P, Akinkuolie A, Chu A, Shah S, Kraus W, Craig D et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol. Journal of the American Heart Association. 2017;6(7).

12. Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. New England Journal of Medicine. 2004;350(15):1495-1504.

13. Cannon C, IMPROVE-IT Investigators. Ezetimibe plus a Statin after Acute Coronary Syndromes. New England Journal of Medicine. 2015;373(15):1473-1477.

14. Sniderman A, Thanassoulis G, Glavinovic T, Navar A, Pencina M, Catapano A et al. Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiology. 2019;4(12):1287.

15. Burgess S, Ference B, Staley J, Freitag D, Mason A, Nielsen S et al. LPA variants, risk of coronary disease, and estimated clinical benefit of lipoprotein(a) lowering therapies: A mendelian randomization analysis. Atherosclerosis. 2018;275:e4.